News Column

TapImmune Appoints Leading Immunotherapy Researcher to Chair Scientific Advisory Board

June 23, 2014



By a News Reporter-Staff News Editor at Cancer Gene Therapy Week -- TapImmune Inc. (OTCQB:TPIV) is pleased to announce that Dr. Keith Knutson, PhD (www.vgtifl.org/keith-knutson-phd) has been appointed to chair the company's scientific advisory board. Dr. Knutson is Director of the Cancer Vaccines and Immune Therapies Program at the Vaccine & Gene Therapy Institute of Florida, a nonprofit biomedical research institute in Port St. Lucie, FL (VGTI Florida). TapImmune has licensed cancer vaccine technologies originating from Dr. Knutson's former laboratory at the Mayo Clinic, which are currently completing Phase I clinical trials in breast and ovarian cancer. The start of Phase II clinical studies in planned for the end of 2014. Glynn Wilson, TapImmune CEO said, "We are delighted to have someone with Keith's vision and scientific knowledge to lead our scientific advisory board. As a recognized leader in immunotherapy of breast and ovarian cancer, it is a great to have his input into the Company's clinical development programs. Under Dr. Knutson's leadership, TapImmune will continue to build a world-class scientific advisory board to review and advance all scientific programs."

"I have been impressed by the comprehensive approach to immunotherapy at TapImmune which looks at both T-cell stimulation and antigen presentation," said Dr. Knutson. "I look forward to leading this advisory board and recruiting additional scientific input that will serve to provide the best scientific approaches for the Company."

Before joining VGTI Florida, Dr. Knutson was the Director of the Mayo Clinic Cancer Center Immunology and Immunotherapy Program at the Mayo Clinic, Rochester, Minnesota. He retains adjunct faculty positions at the Mayo Clinic and Florida Atlantic University. Until recently, he was a standing member of the U.S. Department of Defense'sBreast Cancer Research Program Integration Panel and is a current member of the Tumor Microenvironment Study Section at the National Institutes of Health. He was previously the Co-Director of the Mayo Clinic Immune Monitoring Core which engaged in providing a variety of different immune monitoring and phenotyping services for research purposes across a variety of scientific disciplines including tumor immunology, rheumatoid arthritis, and infectious diseases (see also TapImmune Inc.).

Keywords for this news article include: Oncology, TapImmune Inc, Cancer Vaccines, Biological Products, Cancer Gene Therapy.

Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2014, NewsRx LLC


For more stories covering the world of technology, please see HispanicBusiness' Tech Channel



Source: Cancer Gene Therapy Week


Story Tools






HispanicBusiness.com Facebook Linkedin Twitter RSS Feed Email Alerts & Newsletters